Conference Call with Cipla Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Cipla announced Q4FY23 & FY23 results: Q4FY23: Income from Operations: Rs 5,739 crore, up 9% YoY EBITDA Margin: Rs 1,174 crore Adjusted PAT: Rs 708 crore FY23: Income from Operations: Rs 22,753 crore, up 5% YoY EBITDA Margin: Rs 5,027 crore Adjusted PAT: Rs 2,984 crore “I am pleased to share that we continue to make significant progress across our focused markets. In FY23, we recorded the highest-ever revenue with EBITDA crossing Rs 5,000 crore for the first time. Our One-India business continued the double-digit trajectory growing at 13% ex-Covid during the year led by branded prescription and sustained growth across our acute and chronic therapies. Our continued focus on the differentiated portfolio has strengthened our US business which posted the highest-ever quarterly revenue at USD 204 million and USD 733 million for FY23. Adjusting for covid, our core operating profitability continues to be strong at ~23% expanding by 100 bps over last year. We are excited for the upcoming year, where we look forward to deepening our leadership in branded markets and expanding our differentiated pipeline in the US.” said Umang Vohra, MD and Global CEO, Cipla. Result PDF